Aptus Pharma
New to Zerodha? Sign-up for free.
New to Zerodha? Sign-up for free.
Get instant stock alerts
- Share Price
- Financials
- Revenue mix
- Shareholdings
- Peers
- Forensics
Share Price
Coming soon
- 5D
- 1M
- 6M
- YTD
- 1Y
- 5Y
- MAX
Financials
-
Summary
-
Profit & Loss
-
Balance sheet
-
Cashflow
This data is currently unavailable for this company.
| (In Cr.) |
|---|
| (In Cr.) | ||||
|---|---|---|---|---|
|
This data is currently unavailable for this company. |
| (In %) |
|---|
| (In Cr.) |
|---|
| Financial Year (In Cr.) |
|---|
Revenue mix
-
Product wise
-
Location wise
Revenue Mix
This data is currently unavailable for this company.
Revenue Mix
This data is currently unavailable for this company.
Forensics
Recent events
-
News
-
Corporate Actions
Aptus Pharma said its board had approved a proposed ₹44.88 crore preferential issue to identified investors, subject to shareholder and regulatory approvals, with ₹25 crore earmarked for land, a manufacturing plant structure, hi-tech storage facilities and vehicles. It outlined plans to meet about 20% of its product requirements through in-house manufacturing, expand its distribution network across India and explore markets in Africa, the Middle East and Latin America.
Powered by Tijori
Aptus Pharma said its board had approved a proposed ₹44.88 crore preferential issue to identified investors, subject to shareholder and regulatory approvals, with ₹25 crore earmarked for land, a manufacturing plant structure, hi-tech storage facilities and vehicles. It outlined plans to meet about 20% of its product requirements through in-house manufacturing, expand its distribution network across India and explore markets in Africa, the Middle East and Latin America.
Powered by Tijori
Aug 24 (Reuters) - Aptus Pharma Ltd APTM.BO:
APTUS PHARMA - APPROVES PROPOSAL TO RAISE 448.8 MILLION RUPEES VIA PREFERENTIAL EQUITY ISSUE
Source text: ID:nBSE6GNct1
Further company coverage: APTM.BO
(([email protected];))
Aug 24 (Reuters) - Aptus Pharma Ltd APTM.BO:
APTUS PHARMA - APPROVES PROPOSAL TO RAISE 448.8 MILLION RUPEES VIA PREFERENTIAL EQUITY ISSUE
Source text: ID:nBSE6GNct1
Further company coverage: APTM.BO
(([email protected];))
Aptus Pharma's board approved the proposed preferential issue of 16,02,870 equity shares at ₹280 each, amounting to ₹44.88 crore, for allotment to 190 investors. The price was based on a valuation report, and the issue remained subject to shareholder and other approvals; the company scheduled its 16th annual general meeting for September 14.
Powered by Tijori
Aptus Pharma's board approved the proposed preferential issue of 16,02,870 equity shares at ₹280 each, amounting to ₹44.88 crore, for allotment to 190 investors. The price was based on a valuation report, and the issue remained subject to shareholder and other approvals; the company scheduled its 16th annual general meeting for September 14.
Powered by Tijori
Aptus Pharma's board approved a proposed preferential issue of 16,10,100 equity shares to 192 investors, subject to shareholder and other necessary approvals. The issue price remained to be fixed after a valuation report and a subsequent board decision, while shareholders were due to consider the allotment at an annual general meeting on September 14.
Powered by Tijori
Aptus Pharma's board approved a proposed preferential issue of 16,10,100 equity shares to 192 investors, subject to shareholder and other necessary approvals. The issue price remained to be fixed after a valuation report and a subsequent board decision, while shareholders were due to consider the allotment at an annual general meeting on September 14.
Powered by Tijori
Aptus Pharma's board on Friday approved a fund raising of up to ₹51 crore to expand its business operations. The plan includes a preferential allotment of securities worth ₹35 crore, debt financing of ₹10 crore, and internal accruals of ₹6 crore. The preferential allotment is subject to shareholder and regulatory approvals, with detailed terms including pricing and allottee identities yet to be finalized. The company said the board delegated authority to managing director Tejas Hathi to identify and negotiate with prospective investors. Aptus Pharma, with a market capitalization of ₹378 crore, had previously intimated the board meeting on June 9. The fund raising represents a significant capital infusion relative to the company's size.
Powered by Tijori
Aptus Pharma's board on Friday approved a fund raising of up to ₹51 crore to expand its business operations. The plan includes a preferential allotment of securities worth ₹35 crore, debt financing of ₹10 crore, and internal accruals of ₹6 crore. The preferential allotment is subject to shareholder and regulatory approvals, with detailed terms including pricing and allottee identities yet to be finalized. The company said the board delegated authority to managing director Tejas Hathi to identify and negotiate with prospective investors. Aptus Pharma, with a market capitalization of ₹378 crore, had previously intimated the board meeting on June 9. The fund raising represents a significant capital infusion relative to the company's size.
Powered by Tijori
March 26 (Reuters) - Aptus Pharma Ltd APTM.BO:
APTUS PHARMA LTD - APPROVES BONUS ISSUE IN 3:2 RATIO
Source text: ID:nBSE5dkkWQ
Further company coverage: APTM.BO
(([email protected];))
March 26 (Reuters) - Aptus Pharma Ltd APTM.BO:
APTUS PHARMA LTD - APPROVES BONUS ISSUE IN 3:2 RATIO
Source text: ID:nBSE5dkkWQ
Further company coverage: APTM.BO
(([email protected];))
March 24 (Reuters) - Aptus Pharma Ltd APTM.BO:
RECOMMENDS ISSUE OF BONUS EQUITY SHARES IN RATIO OF 3:2
Source text: ID:nBSE1lJLS1
Further company coverage: APTM.BO
(([email protected];))
March 24 (Reuters) - Aptus Pharma Ltd APTM.BO:
RECOMMENDS ISSUE OF BONUS EQUITY SHARES IN RATIO OF 3:2
Source text: ID:nBSE1lJLS1
Further company coverage: APTM.BO
(([email protected];))
March 17 (Reuters) - Aptus Pharma Ltd APTM.BO:
TO CONSIDER BONUS EQUITY SHARES
Source text: ID:nBSE5gPZvP
Further company coverage: APTM.BO
(([email protected];;))
March 17 (Reuters) - Aptus Pharma Ltd APTM.BO:
TO CONSIDER BONUS EQUITY SHARES
Source text: ID:nBSE5gPZvP
Further company coverage: APTM.BO
(([email protected];;))
Feb 26 (Reuters) - Aptus Pharma Ltd APTM.BO:
APTUS PHARMA LTD - EXPANDS INTO LIFE-SAVING INJECTABLES AND ICU CARE
Source text: ID:nBSE7TgRYp
Further company coverage: APTM.BO
(([email protected];))
Feb 26 (Reuters) - Aptus Pharma Ltd APTM.BO:
APTUS PHARMA LTD - EXPANDS INTO LIFE-SAVING INJECTABLES AND ICU CARE
Source text: ID:nBSE7TgRYp
Further company coverage: APTM.BO
(([email protected];))
More Micro Cap Ideas
See similar 'Micro' cap companies with recent activity
Promoter Buying
Companies where the promoters are bullish
Capex
Companies investing on expansion
Superstar Investor
Companies where well known investors have invested
Popular questions
- Business
- Financials
- Share Price
- Shareholdings
What does Aptus Pharma do?
Aptus Pharma is engaged in the business of marketing, and distribution of finished pharmaceutical formulations. It operates through a contract manufacturing model. It provides a diverse range of pharmaceutical products catering to various therapeutic categories including anti-infectives, gastrointestinal, antacids, anti-allergic and respiratory, etc.
Who are the competitors of Aptus Pharma?
Aptus Pharma major competitors are Zota Health Care, Sunrest Lifescience, Lincoln Pharma. Market Cap of Aptus Pharma is ₹793 Crs. While the median market cap of its peers are ₹1,005 Crs.
Is Aptus Pharma financially stable compared to its competitors?
Aptus Pharma seems to be financially stable compared to its competitors. The probability of it going bankrupt or facing a financial crunch seem to be lower than its immediate competitors.
Does Aptus Pharma pay decent dividends?
The company seems to be paying a very low dividend. Investors need to see where the company is allocating its profits. Aptus Pharma latest dividend payout ratio is 0% and 3yr average dividend payout ratio is 0%
How has Aptus Pharma allocated its funds?
Companies resources are allocated to majorly unproductive assets like Inventory, Accounts Receivable
How strong is Aptus Pharma balance sheet?
Balance sheet of Aptus Pharma is strong. It shouldn't have solvency or liquidity issues.
Is the profitablity of Aptus Pharma improving?
Yes, profit is increasing. The profit of Aptus Pharma is ₹7.95 Crs for TTM, ₹4.62 Crs for Mar 2026 and ₹3.1 Crs for Mar 2025.
Is the debt of Aptus Pharma increasing or decreasing?
Yes, The net debt of Aptus Pharma is increasing. Latest net debt of Aptus Pharma is ₹10.31 Crs as of Sep-26. This is greater than Mar-26 when it was ₹5.61 Crs.
Is Aptus Pharma stock expensive?
Yes, Aptus Pharma is expensive. Latest PE of Aptus Pharma is 171, while 3 year average PE is 77.67. Also latest EV/EBITDA of Aptus Pharma is 43.88 while 3yr average is 38.77.
Has the share price of Aptus Pharma grown faster than its competition?
Aptus Pharma has given better returns compared to its competitors. Aptus Pharma has grown at ~733.55% over the last 1yrs while peers have grown at a median rate of -12.06%
Is the promoter bullish about Aptus Pharma?
Promoters stake in the company seems stable, and we need to go through filings and allocation of resources to gauge promoter bullishness. Latest quarter promoter holding in Aptus Pharma is 72.89% and last quarter promoter holding is 72.89%.
Are mutual funds buying/selling Aptus Pharma?
There is Insufficient data to gauge this.